Novartis Ag · SIX:NOVN
Novartis — Q4 2024 Earnings Presentation
77 slides from Novartis's earnings presentation, Jan 31, 2025
Slide 1: Q4 2024 Results Investor presentation
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Q4 2024 Results Q4 2024 Results Investorpresentation Investor presentation January31, January 31, 2025 2025 Novartis Q4 Results | January 31, 2025 1
Slide 2: Disclaimer
Content Click below to navigate Disclaimer through the document Company overview This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potential,” Financial re
Slide 3: Company overview
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Company overview Company overview Vas Narasimhan, M.D. Chief Executive Officer Vas Narasimhan, M.D. Chief Executive Officer Novartis Q4 Results | January 31, 2025 3
Slide 4: Novartis delivered one of the strongest performances in our history in 2024
Content Click below to navigate Novartis delivered one of the strongest performances in our history in 2024 through the document Company overview Financial review Conclusions Appendix References 1. Constant currencies (cc) and core results are non-IFRS measures. An explanation of non-IFRS measures c
Slide 5: Priority brands continued to drive robust growth
GROWTH Content Click below to navigate Priority brands continued to drive robust growth, demonstrating our replacement power through the document Company overview Financial review FY sales Conclusions Sales Growth vs. PY Growth vs. PY USD million USD million cc Appendix 7,822 1,787 31% References 6,
Slide 6: Entresto achieved FY sales of USD 7.8bn
GROWTH Content Click below to navigate Entresto® achieved FY sales of USD 7.8bn, +31% cc vs. PY through the document Company overview Financial review Sales evolution US weekly TRx1 Continued strong momentum in Q4 USD m, % cc Total prescriptions (000) • US: +41% with ~9k NBRx per week Conclusions FY
Slide 7: Cosentyx FY sales topped USD 6bn
GROWTH Content Click below to navigate Cosentyx® FY sales topped USD 6bn, +25% cc, fueled by new launches and expansion in core indications through the document Company overview Financial review Sales evolution Strong demand-driven growth in Q4 USD m, % cc • US: +36%, driven by HS and IV launches Co
Slide 8: Kesimpta FY sales grew +49% cc to USD 3.2bn
GROWTH Content Click below to navigate Kesimpta® FY sales grew +49% cc to USD 3.2bn, outpacing both B-cell and MS market growth through the document Company overview Financial review Sales evolution Solid volume and market share gains in Q4 USD m, % cc • US: +42%, with TRx growth (+29%) outpacing B-
Slide 9: Kisqali FY sales grew +49% cc to USD 3.0bn
GROWTH Content Click below to navigate Kisqali® FY sales grew +49% cc to USD 3.0bn, reflecting market leadership in mBC NBRx and strong early launch uptake in eBC through the document Company overview Financial review Conclusions Appendix References See page 76 for references (footnotes 1-3). Consta
Slide 10: Pluvicto delivered FY sales of USD 1.4bn
GROWTH Content Click below to navigate Pluvicto® delivered FY sales of USD 1.4bn (+42% cc) in post-taxane setting, while laying foundation for anticipated pre-taxane launch in H1 2025 through the document Company overview ® Financial review Sales evolution Sustained growth in post-taxane setting in
Slide 11: Leqvio continued steady trajectory, +114% cc FY growth
GROWTH Content Click below to navigate Leqvio® continued steady trajectory, delivering +114% cc FY growth through the document Company overview Financial review Sales evolution US: Growth outpacing advanced lipid-lowering market1,2 USD m, % cc • 3,230 health systems, representing 68% of aLLT market
Slide 12: Scemblix FY sales grew +68% cc
GROWTH Content Click below to navigate Scemblix® FY sales grew +68% cc, with continued momentum in 3L+ CML and promising early lines launch in US through the document Company overview Financial review Sales evolution Market leader in 3L+ CML USD m, % cc • US: NBRx share of 49%, 3x higher than next c
Slide 13: Phase 3 ASC4FIRST 96-week data reinforce Scemblix superior efficacy
INNOVATION Content Click below to navigate Phase 3 ASC4FIRST 96-week data reinforce Scemblix® superior efficacy with favorable safety and tolerability profile through the document Company overview Financial review Conclusions Appendix References Error bars represent 95% CIs. The common treatment dif
Slide 14: Fabhalta on track across first three core indications
GROWTH Content Click below to navigate Fabhalta® on track across first three core indications through the document Company overview Financial review Conclusions PNH IgAN Continued strong uptake in rare disease setting Encouraging early launch signals in US Appendix US Ex-US Strong access pull-throug
Slide 15: We continued to advance our pipeline in Q4
INNOVATION Content Click below to navigate We continued to advance our pipeline in Q4 through the document Company overview Financial review 2024 selected key events (expected) Conclusions H1 2024 H2 2024 Status as of end Q4 Regulatory Fabhalta® PNH EU, JP EU, JP and China approval in Q2 Appendix de
Slide 16: Phase 3 STEER study of OAV101 IT met primary endpoint
INNOVATION Content Click below to navigate Phase 3 STEER study of OAV101 IT met primary endpoint in children and young adults with spinal muscular atrophy through the document Company overview Financial review First investigational gene therapy to provide clinical benefit in treatment-naive patients
Slide 17: Bolstered Neuroscience pipeline with in-licensing of votoplam
INNOVATION Content Click below to navigate Bolstered Neuroscience pipeline with in-licensing of votoplam (PTC518), potential first oral disease-modifying therapy for Huntington’s Disease through the document Company overview Financial review Significant unmet need in HD Ph2 PIVOT-HD study ongoing Co
Slide 18: Expect to continue our innovation momentum in 2025
INNOVATION Content Click below to navigate Expect to continue our innovation momentum in 2025 through the document Company overview Financial review 2025 selected key events (expected) Conclusions Appendix References 15+ Key approvals or submissions 10+ Key readouts (six pivotal) 10+ Key study initi
Slide 19: Confident in our mid-term guidance of +5% cc sales CAGR
Content Click below to navigate Confident in our mid-term guidance of +5% cc sales CAGR 2024-2029 and 40%+ core margin by 2027 through the document Company overview Financial review Mid-term guidance Conclusions 2024-2029 +5% (cc) expected sales CAGR (previous guidance 2023-2028) Illustrative net sa
Slide 20: Financial review and 2025 guidance
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Financial review Financial review References and 2025 guidance and 2025 guidance Harry Kirsch Chief Financial Officer Harry Kirsch Chief Financial Officer Novartis Q4 Results | January 31, 202
Slide 21: Strong track record of sales growth with margin expansion in 2024
FINANCIAL PROFILE Content Click below to navigate Novartis continues strong track record of sales growth with margin expansion in 2024 through the document Company overview Financial review Continuing operations1 performance, numbers restated post-Sandoz spin-off Conclusions Net sales Core OpInc2 Co
Slide 22: In 2024, we met and exceeded our full-year guidance
FINANCIAL PROFILE Content Click below to navigate In 2024, we met and exceeded our full-year guidance through the document Company overview Financial review Continuing operations1 Conclusions In cc2 Appendix Sales Core OpInc References FY guidance Expected to grow Expected to grow (as per Q3 2024) l
Slide 23: Robust top and bottom-line growth during Q4 and FY
FINANCIAL PROFILE Content Click below to navigate Robust top and bottom-line growth during Q4 and FY, with record margin and free cash flow in 2024 through the document Company overview Financial review Continuing Operations1,2 Q4 Q4 Change vs. PY FY FY Change vs. PY Conclusions USD million 2023 202
Slide 24: Continued focus on Free Cash Flow generation
FINANCIAL PROFILE Content Click below to navigate Continued focus on Free Cash Flow generation through the document Company overview Financial review Free Cash Flow1 Conclusions USD bn, period rates +24% Appendix +16% CAGR 2024 growth driven References +9% by higher core operating income 2022 2023 2
Slide 25: Continuing our shareholder-friendly capital allocation strategy
FINANCIAL PROFILE Content Click below to navigate Continuing our shareholder-friendly capital allocation strategy through the document Company overview Financial review Conclusions Investing in the business Returning capital to shareholders Appendix Investments in organic business Consistently growi
Slide 26: Novartis proposes 3.50 CHF/share dividend at the AGM
FINANCIAL PROFILE Content Click below to navigate Novartis proposes 3.50 CHF/share1 dividend at the AGM; 28th consecutive dividend increase in CHF since 1996 through the document Company overview Financial review CHF dividend USD dividend Conclusions 2024 proposal: 2023: Appendix CHF 3.501/USD 3.874
Slide 27: Novartis 2025 full year guidance
FINANCIAL PROFILE Content Click below to navigate Novartis 2025 full year guidance Expected, barring unforeseen events; growth vs. PY in cc1 through the document Company overview Financial review Conclusions Net sales Core operating income Appendix expected to grow expected to grow mid- to high sing
Slide 28: Expect continued strong volume growth from priority brands in 2025
FINANCIAL PROFILE Content Click below to navigate Expect continued strong volume growth from priority brands in 2025; H2 impacted by potential Tasigna®, Promacta® and Entresto® US Gx entry2 through the document Company overview Financial review Conclusions Appendix References 1. Core results and con
Slide 29: Expected currency impact for Q1 and full year 2025
FINANCIAL PROFILE Content Click below to navigate Expected currency impact for Q1 and full year 2025 through the document Company overview Financial review Conclusions Appendix References 1. Core results are non-IFRS measures as defined on page 47 of Condensed Financial Report. Novartis Q4 Results |
Slide 30: Conclusions
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Conclusions Conclusions Vas Narasimhan, M.D. Chief Executive Officer Vas Narasimhan, M.D. Chief Executive Officer Novartis Q4 Results | January 31, 2025 30
Slide 31: Continued strong business momentum in Q4
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Continued Met and exceeded Continued to Expect to continue strong business our full-year advance our strong sales growth momentum in Q4, guidance pipeline, including with margin References del
Slide 32: Appendix
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Appendix Financial performance Innovation: Clinical trials Abbreviations References Appendix Novartis Q4 Results | January 31, 2025 32
Slide 33: Key innovation milestones in 2025
INNOVATION Content Click below to navigate Key innovation milestones in 2025 through the document Company overview 2025 selected key events (expected) H1 2025 H2 2025 Financial review Regulatory Atrasentan IgAN US Fabhalta® (iptacopan) C3G US, JP EU decisions Pluvicto® mCRPC, pre-taxane US Conclusio
Slide 34: Our pipeline projects at a glance
INNOVATION Content Click below to navigate Our pipeline projects at a glance through the document Company overview Financial review Phase 1/2 Phase 3 Registration Total Conclusions Oncology 23 8 4 35 Appendix Solid tumors 18 3 4 25 Innovation: Pipeline overview Hematology 5 5 0 10 Financial performa
Slide 35: Novartis pipeline in Phase 1
INNOVATION Content Click below to navigate Novartis pipeline in Phase 1 16 lead indications through the document Lead indication Company overview Oncology Neuroscience Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) DFT383 DFT383 CTNS gene delivery Cystinosis Solid tumors Financi
Slide 36: Novartis pipeline in Phase 2
INNOVATION Content Click below to navigate Novartis pipeline in Phase 2 16 lead indications through the document Lead indication Company overview Oncology Immunology Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) DFV890 DFV890 NLRP3 inhibitor Osteoarthritis Solid tumors Financia
Slide 37: Novartis pipeline in Phase 3
INNOVATION Content Click below to navigate Novartis pipeline in Phase 3 6 lead indications through the document Lead indication Company overview Oncology Neuroscience Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) BAF312 Mayzent® S1P1,5 receptor modulator Multiple sclerosis, ped
Slide 38: Novartis pipeline in registration
INNOVATION Content Click below to navigate Novartis pipeline in registration 1 lead indication through the document Company overview Oncology Code Name Mechanism Indication(s) Solid tumors Financial review AAA6011 Lutathera® Radioligand therapy target SSTR Gastroenteropancreatic neuroendocrine tumor
Slide 39: Novartis submission schedule: New Molecular Entities
INNOVATION Content Click below to navigate Novartis submission schedule New Molecular Entities: Lead and supplementary indications through the document Company overview CRM Immunology Neuroscience Oncology Non-core TA project Financial review 2025 2026 2027 ≥2028 Conclusions remibrutinib ianalumab z
Slide 40: Submission schedule: existing brands
INNOVATION Content Click below to navigate Novartis submission schedule Supplementary indications for existing brands through the document Company overview CRM Immunology Neuroscience Oncology Non-core TA project Financial review 2025 2026 2027 ≥2028 Conclusions Cosentyx® Cosentyx® Fabhalta® Fabhalt
Slide 41: Net debt increased by USD 5.9bn
FINANCIAL PROFILE Content Click below to navigate Net debt increased by USD 5.9bn due to share buybacks, the annual dividend and M&A, partially offset by FCF through the document Company overview Financial review USD bn Conclusions -5.9 Appendix Innovation: Pipeline overview Financial performance In
Slide 42: Clinical Trials Update
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Clinical Trials Update > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience IR Clinical Includes
Slide 43: Cardiovascular, Renal and Metabolic
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Cardiovascular, Renal and Metabolic > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience IR Clin
Slide 44: atrasentan - ETA receptor antagonist
Content Click below to navigate atrasentan - ETA receptor antagonist through the document Company overview NCT04573478 ALIGN (CHK01-01) Financial review Indication IgA nephropathy Phase Phase 3 Conclusions Patients 380 Primary Change in proteinuria Time Frame: Up to Week 24 or approximately 6 months
Slide 45: Fabhalta - CFB inhibitor
Content Click below to navigate Fabhalta® - CFB inhibitor Fabhalta® - CFB inhibitor through the document Company overview NCT04578834 APPLAUSE-IgAN (CLNP023A2301) NCT05755386 APPARENT (CLNP023B12302) Financial review Indication IgA nephropathy Indication Immune complex-mediated membranoproliferative
Slide 46: Leqvio - siRNA (regulation of LDL-C)
Content Click below to navigate Leqvio® - siRNA (regulation of LDL-C) Leqvio® - siRNA (regulation of LDL-C) through the document Company overview NCT03705234 ORION-4 (CKJX839B12301) NCT05030428 VICTORION-2P (CKJX839B12302) Financial review Indication Hypercholesterolemia inc. Heterozygous Familial H
Slide 47: Leqvio - siRNA (regulation of LDL-C)
Content Click below to navigate Leqvio® - siRNA (regulation of LDL-C) Leqvio® - siRNA (regulation of LDL-C) through the document Company overview NCT04652726 ORION-16 (CKJX839C12301) NCT04659863 ORION-13 (CKJX839C12302) Financial review Indication Hyperlipidemia, pediatrics Indication Hyperlipidemia
Slide 48: Leqvio - siRNA (regulation of LDL-C)
Content Click below to navigate Leqvio® - siRNA (regulation of LDL-C) Leqvio® - siRNA (regulation of LDL-C) through the document Company overview NCT05739383 VICTORION-1P (CKJX839D12302) NCT05763875 V-Mono (CKJX839D12304) Financial review Indication CVRR (Primary prevention) Indication CVRR (Primary
Slide 49: pelacarsen - Antisense oligonucleotide targeting Lp(a)
Content Click below to navigate pelacarsen - Antisense oligonucleotide (ASO) through the document targeting Lp(a) Company overview NCT04023552 Lp(a)HORIZON (CTQJ230A12301) Financial review Indication Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein(a) Con
Slide 50: zigakibart - Anti-APRIL
Content Click below to navigate zigakibart - Anti-APRIL through the document Company overview NCT05852938 BEYOND (CFUB523A12301) Financial review Indication IgA nephropathy Phase Phase 3 Conclusions Patients 292 Appendix Primary Change in proteinuria [ Time Frame: 40 weeks or approximately 9 months
Slide 51: Immunology
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Immunology > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience IR Clinical Studies > O ncology
Slide 52: Cosentyx - IL-17A inhibitor
Content Click below to navigate Cosentyx® - IL-17A inhibitor Cosentyx® - IL-17A inhibitor through the document Company overview NCT05767034 REPLENISH (CAIN457C22301) NCT04930094 GCAPTAIN (CAIN457R12301) Financial review Indication Polymyalgia rheumatica Indication Giant cell arteritis Phase Phase 3
Slide 53: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell through the document depletor Company overview NCT05126277 SIRIUS-LN (CVAY736K12301) Financial review Indication Lupus Nephritis Phase Phase 3 Conclusions Patients 420 Primary Outcome Frequency and percentage of parti
Slide 54: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell through the document depletor depletor Company overview NCT05349214 NEPTUNUS-2 (CVAY736A2302) NCT05350072 NEPTUNUS-1 (CVAY736A2301) Financial review Indication Sjögre
Slide 55: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell through the document depletor depletor Company overview NCT05639114 SIRIUS-SLE 1 (CVAY736F12301) NCT05624749 SIRIUS-SLE 2 (CVAY736F12302) Financial review Indication
Slide 56: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell through the document depletor Company overview NCT06470048 (CVAY736S12201) Financial review Indication Systemic scleroderma Phase Phase 2 Conclusions Patients 200 Primary 3/5 Revised Composite Response Index in System
Slide 57: remibrutinib - BTK inhibitor
Content Click below to navigate remibrutinib - BTK inhibitor through the document Company overview NCT05976243 (CLOU064M12301) Financial review Indication Chronic inducible urticaria Phase Phase 3 Conclusions Patients 348 Primary 1. Proportion of participants with complete response in Total Fric Sco
Slide 58: Neuroscience
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Neuroscience > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience IR Clinical Studies > O ncolog
Slide 59: Fabhalta - CFB inhibitor
Content Click below to navigate Fabhalta® - CFB inhibitor through the document Company overview NCT123456 APPRAISE (CLNP023Q12301) Financial review Indication Generalized Myasthenia Gravis Phase Phase 3 Conclusions Patients 146 Primary Change from baseline to Month 6 Appendix in Myasthenia Gravis Ac
Slide 60: Mayzent - S1P1,5 receptor modulator
Content Click below to navigate Mayzent® - S1P1,5 receptor modulator through the document Company overview NCT04926818 NEOS (CBAF312D2301) Financial review Indication Multiple sclerosis, pediatrics Phase Phase 3 Conclusions Patients 120 Primary Annualized relapse rate (ARR) in target pediatric parti
Slide 61: remibrutinib - BTK inhibitor
Content Click below to navigate remibrutinib - BTK inhibitor remibrutinib - BTK inhibitor through the document Company overview NCT05147220 REMODEL-1 (CLOU064C12301) NCT05156281 REMODEL-2 (CLOU064C12302) Financial review Indication Multiple sclerosis Indication Multiple sclerosis Phase Phase 3 Phase
Slide 62: remibrutinib - BTK inhibitor
Content Click below to navigate remibrutinib - BTK inhibitor through the document Company overview NCT06744920 RELIEVE (CLOU064O12301) Financial review Indication Myasthenia Gravis Phase Phase 3 Conclusions Patients 180 Primary Change from baseline to Month 6 in Myasthenia Gravis Activity of Daily L
Slide 63: Zolgensma - SMN1 gene replacement therapy
Content Click below to navigate Zolgensma® - SMN1 gene replacement therapy Zolgensma® - SMN1 gene replacement therapy through the document Company overview NCT05089656 STEER (COAV101B12301) NCT05386680 STRENGTH (COAV101B12302) Financial review Indication Spinal muscular atrophy (IT administration) I
Slide 64: Oncology
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Oncology > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience IR Clinical Studies > O ncology >
Slide 65: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell through the document depletor depletor Company overview NCT05653349 VAYHIT1 (CVAY736I12301) NCT05653219 VAYHIT2 (CVAY736Q12301) Financial review Indication 1L Immune
Slide 66: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell through the document depletor Company overview NCT05648968 VAYHIA (CVAY736O12301) Financial review Indication Warm autoimmune hemolytic anemia Phase Phase 3 Conclusions Patients 90 Primary Binary variable indicating w
Slide 67: iptacopan - CFB inhibitor
Content Click below to navigate iptacopan - CFB inhibitor through the document Company overview NCT04889430 APPELHUS (CLNP023F12301) Financial review Indication Atypical haemolytic uraemic syndrome Phase Phase 3 Conclusions Patients 50 Primary Percentage of participants with complete TMA response wi
Slide 68: Pluvicto - Radioligand therapy target PSMA
Content Click below to navigate Pluvicto® - Radioligand therapy target PSMA Pluvicto® - Radioligand therapy target PSMA through the document Company overview NCT04689828 PSMAfore (CAAA617B12302) NCT04720157 PSMAddition (CAAA617C12301) Financial review Indication Metastatic castration-resistant prost
Slide 69: Vijoice - PI3Ki
Content Click below to navigate Vijoice® - PI3Ki through the document Company overview NCT05948943 EPIK-L1 (CBYL719P12201) Financial review Indication Lymphatic Malformation Phase Phase 2/3 Conclusions Patients 230 Primary Outcome Stage 2: Radiological response rate at Week 24 of Stage 2 (adult and
Slide 70: In-market Brands & Global Health
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials In-market Brands & Global Health > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience IR Clinica
Slide 71: cipargamin - PfATP4 inhibitor
Content Click below to navigate cipargamin - PfATP4 inhibitor through the document Company overview NCT04675931 KARISMA (CKAE609B12201) Financial review Indication Malaria severe Phase Phase 2 Conclusions Patients 252 Primary Percentage of participants achieving at least 90% reduction in Plasmodium
Slide 72: ganaplacide/lumefantrine
Content Click below to navigate ganaplacide/lumefantrine - Non-artemisinin through the document plasmodium falciparum inhibitor Company overview NCT05842954 KALUMA (CKLU156A12301 ) Financial review Indication Malaria, uncomplicated Phase Phase 3 Conclusions Patients 1500 Primary PCR-corrected adequa
Slide 73: Rydapt - Multi-targeted kinase inhibitor
Content Click below to navigate Rydapt® - Multi-targeted kinase inhibitor through the document Company overview NCT03591510 (CPKC412A2218) Financial review Indication Acute myeloid leukemia, pediatrics Phase Phase 2 Conclusions Patients 20 Primary Occurrence of dose limiting toxicities Appendix Outc
Slide 74: Abbreviations
Content Click below to navigate Abbreviations through the document Company overview Financial review Abbreviation Full Form Abbreviation Full Form Conclusions ACS Acute Coronary Syndrome IL Interleukin Adj.BC Adjuvant Breast Cancer IV Intravenous Appendix aLLT Advanced Lipid Lowering Therapy IVH Int
Slide 75: References 1/3
Content Click below to navigate References 1/3 through the document Company overview Entresto® (slide 6 references) Financial review 1 IQVIA National Prescription Audit. Approved indications differ by geography. Examples include “indicated to reduce the risk of cardiovascular death and hospitalizati
Slide 76: References 2/3
Content Click below to navigate References 2/3 through the document Company overview Kisqali® (slide 9 references) Financial review 1 IQVIA Market Sizing Monthly Report, November 2024; Data lag: ~ 2 months. 2 Of CDK4/6 mBC market, US rolling 3 months ending November 2024, IQVIA Breast Cancer Market
Slide 77: References 3/3
Content Click below to navigate References 3/3 through the document Company overview OAV101 IT (slide 16 references) Financial review 1 Oskoui M, et al. SUNFISH Parts 1 and 2: 4-year efficacy and safety data of risdiplam in types 2 and 3 Spinal Muscular Atrophy (SMA). Available at: https://medically